This study is for patients that have been diagnosed with Relapsed/Refractory Acute Myeloid Leukemia (AML) or in Newly Diagnosed Older (?65 Years) AML Subjects. The investigational drug in this study is Azacitidine (AZA) and Pembroluzimab (KEYTRUDA). The purpose of this study is to determine the safety, tolerability and efficacy of Azacitidine (AZA) in combination with Pembrolizumab (also known as KEYTRUDA TM) in relapsed and refractory acute myeloid leukemia (AML) subjects, and also in older (?65 years) newly diagnosed AML subjects who are not candidates for intensive induction chemotherapy. Participants can expect to be in this study for up to 2 1/2 years.
This study is for adult patients that are suspected to have or were recently diagnosed with acute myeloid leukemia (AML) and have not yet received treatment for AML. The investigational drug in this study is vosaroxin. The participants can expect to be in this study until they have completed both induction therapies. However, after treatment, they will be in follow-up that consists of disease status updates every 3 months indefinitely.
This study is for patient that has been diagnosed with Acute Myeloid Leukemia (AML). The experimental (investigational) drug that is being tested for treatment of acute myeloid leukemia (AML), called CX-01. The purpose of this study is to find out whether or not the addition of the study drug, CX-01, to standard of care treatment for AML increases the rate of remission. Participants can expect to be in this study for approximately 18 months.
This study is for patients that have been diagnosed with previously untreated Intermediate or High-risk myelodysplastic syndrome (MDS). The investigational drug in this study is vadastuximab talirine (SGN-CD33A). The purpose of this study is to evaluate escalating doses of vadastuximab talirine and compare the overall response rate between 2 study arms. Participants can expect to be in the study for up to approximately 39 months.
This study is for patients that have been newly diagnosed with acute myelogenous leukemia (AML). The investigational drug in this study AG-120 or AG-221. The purpose of this study is to determine the safety and tolerability of the drugs AG-120 or AG-221 when administered with standard treatment for AML. Participants can expect to be in the study until they experience unacceptable side effects, the disease worsens, proceed to transplant or if the doctor decides it is in their best interest to stop taking the drug for up to 1 year after the first dose of induction therapy.
This study is for patients that have been diagnosed with types of non-Hodgkin lymphoma (NHL) that affect the B cells of the immune system. The investigational drug in this study is SGN-CD19B. The purpose of this study is to test the safety of different doses of SGN-CD19B when given to subjects with NHL. Participants can expect to be in this study for as long their cancer is stable or is getting better with treatment. Once they have stopped treatment, they will have follow up phone calls until the study is closed.
This study is for patients with newly diagnosed myeloma. The study will be looking to explore the drug combination, lenalidomide, bortezomib and dexamethasone alone or when combined with autologous stem cell transplantation to see what side effects it may have and how well it works for treatment of newly diagnosed multiple myeloma.
This study is for adult male and female patients with previously untreated acute myeloid leukemia (AML). The purpose of this study is to compare the effects, good and/or bad of three drug combinations. The first combination is the standard treatment of daunorubicin plus AraC. The second combination is another standard treatment of idarubicin plus AraC. The third combination will add the drug vorinostat to the standard IA therapy. The study team wants to see if the study treatments will get rid of leukemia cells and keep them from coming back for patients who may benefit from stem cell transplant. They also want to find stem cell transplant donors for patients who might benefit from a transplant according to standard practice, beginning at the time patients register for the study. Participants will be asked to take induction treatment for 1-2 months. If a participant gets consolidation, it could take from 1-4 months. Participants may go on to transplant any time in the next year after he/she goes into remission. After participants are finished with the study treatment, the study doctor will ask them to visit the office for follow-up exams for at least 5 years from the time they go into remission.
The primary purposes of this study are to:
?Provide access to cord blood units for recipients whose best choice for a cord blood unit(s) do not meet all FDA standards, but do meet standards set by the NMDP on this study.
?Assess how well and how quickly blood counts return to normal after transplant in recipients on this study.